17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.

PLoS One · 2018 · PMC5826531 · PMID 29481571

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In all three, 17-AAG by itself and in combination with PLX4032 pretreated BRAF WT melanoma cell lines showed highly significant decreases in S phase and increase in G0/G1 arrest.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.